By Steve Usdin
Contributing Editor

WASHINGTON - In its review of Alza Corp.'s Doxil liposomal doxorubicin last week, an FDA advisory panel addressed two issues of broad import for the drug approval process: whether off-label uses should be taken into consideration when making decisions about accelerated approvals and misuse by sponsors of the term "accelerated."